Risk of endophthalmitis following anti-VEGF injection is low

Article

The incidence of suspected endophthalmitis in patients who have received intravitreal anti-vascular endothelial growth factor (VEGF) treatments in a community setting is very low, according to a study published in the May 2008 issue of the American Journal of Ophthalmology.

The incidence of suspected endophthalmitis in patients who have received intravitreal anti-vascular endothelial growth factor (VEGF) treatments in a community setting is very low, according to a study published in the May 2008 issue of the American Journal of Ophthalmology.

Suman Pilli of the Vitreous Retina Macula Consultants of New York and the LuEsther T. Mertz Retinal Research Center at Manhattan Eye, Ear, and Throat Hospital, New York, US and colleagues conducted a retrospective interventional case series of 10254 intravitreal anti-VEGF injections (ranibizumab, n=6347; bevacizumab, n=3501; pegaptanib, n=406) performed in an office setting without preinjection antibiotics between January 5 2005 and October 18 2007.

There were no cases of confirmed endophthalmitis and three cases of suspected endophthalmitis (ranibizumab, n=2; bevacizumab, n=1; pegaptanib, n=0), after which all three patients regained pre-injection visual acuity.

The rate of suspected endophthalmitis was 0.029%, which is comparable to the rate reported when more rigorous preventative measures are taken, such as in a clinical trials setting.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.